Core Insights - CFT1946 is the first and only clinical-stage degrader targeting BRAF V600 mutations, showing promise in disrupting the current treatment landscape for patients with solid tumors [2][10] - Initial clinical data indicate that CFT1946 has a well-tolerated safety profile, dose-dependent pharmacokinetics, and early evidence of anti-tumor activity [3][5][10] - The ongoing Phase 1 trial is expected to provide additional data in 2025, with multiple indication-specific cohorts advancing [7] Safety and Tolerability - CFT1946 has demonstrated a well-tolerated safety profile with no dose-limiting toxicities or treatment-related serious adverse events [3][4] - Adverse events were primarily Grade 1 or Grade 2, with no patients discontinuing therapy due to treatment-related adverse events [4] Pharmacokinetics and Pharmacodynamics - Initial data show dose-dependent bioavailability and effective degradation of BRAF V600E protein, supporting the proof of mechanism for CFT1946 [5][10] - All available post-treatment biopsies indicated successful degradation of the target protein [5] Anti-Tumor Activity - Among 27 evaluable patients, 16 showed a reduction in target metastatic lesions, with two achieving confirmed Partial Response [6] - Notable reductions were observed across various tumor types, including a 67% decrease in a patient with Stage IV BRAF V600K melanoma and a 55% decrease in a patient with Stage IV BRAF V600E pancreatic cancer [6] Future Milestones - The Phase 1 trial will continue with a focus on completing monotherapy dose escalation and exploring combination therapies with cetuximab and trametinib [7] - Full monotherapy dose escalation data and expansion cohort results are anticipated in 2025 [7]

Core Insights - C4 Therapeutics, Inc. announced the release of an abstract detailing clinical data from its Phase 1 trial of CFT1946, a novel BiDAC™ degrader targeting mutant BRAF V600 solid tumors, coinciding with the ESMO Congress 2024 [1][2] - The full abstract includes results with a data cut-off of April 12, 2024, and will be presented at the ESMO Congress on September 13, 2024 [1][2] Group 1 - The Phase 1 trial data will include information on 36 patients, focusing on demographics, safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity as per RECIST 1.1 criteria [2] - The oral presentation is scheduled for September 13, 2024, at 4:10 pm CEST (10:10 am ET) during the proffered paper session [3] - C4 Therapeutics will host a webcast for analysts and investors on the same day at 12:00 pm ET, with a replay available afterward [3] Group 2 - C4 Therapeutics is a clinical-stage biopharmaceutical company focused on targeted protein degradation to develop new medicines [4] - The company's TORPEDO® platform is utilized to design and optimize small-molecule medicines for challenging diseases [4] - CFT1946 is designed to be potent and selective against BRAF V600X mutant targets, showing activity in preclinical studies against BRAF V600E driven diseases and resistant models [5] Group 3 - CFT1946 is currently undergoing a Phase 1 dose escalation study in various BRAF V600X mutant solid tumors, including colorectal cancer, melanoma, and non-small cell lung cancer [5]

Core Insights - C4 Therapeutics, Inc. has appointed Stephen Fawell, Ph.D. to its Board of Directors, while Malcolm Salter retires after nearly a decade of service [1][2] Company Developments - The appointment of Dr. Fawell is expected to leverage his extensive experience in drug discovery and development, particularly in oncology, to advance C4 Therapeutics' mission of developing degrader medicines [2] - Dr. Fawell has nearly 35 years of experience in drug discovery, having transitioned over 25 new drugs into clinical trials during his tenure at AstraZeneca [2] - C4 Therapeutics focuses on targeted protein degradation to create innovative medicines, utilizing its TORPEDO® platform to design small-molecule therapies for difficult-to-treat diseases [3] Leadership Transition - Andrew Hirsch, CEO of C4 Therapeutics, expressed gratitude towards Malcolm Salter for his contributions, which included helping the company become publicly traded and advancing several medicines into clinical development [2] - Dr. Fawell expressed enthusiasm about joining the Board and supporting the management team in advancing the company's portfolio towards pivotal milestones [2]

Core Insights - C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on advancing targeted protein degradation science to develop innovative medicines [3] Group 1: Company Announcements - C4 Therapeutics management will participate in fireside chats at two investor conferences in September 2024 [1] - The first event is the Wells Fargo Healthcare Conference in Boston, MA on September 5, 2024, at 8:45 AM ET [2] - The second event is the 2024 Cantor Global Healthcare Conference in New York, NY on September 18, 2024, at 8:35 AM ET [2] Group 2: Company Overview - C4 Therapeutics is leveraging its TORPEDO® platform to design and optimize small-molecule medicines aimed at difficult-to-treat diseases [3] - The company's degrader medicines utilize the body's natural protein recycling system to degrade disease-causing proteins, potentially overcoming drug resistance and improving patient outcomes [3]

Company Performance - C4 Therapeutics reported a quarterly loss of $0.26 per share, better than the Zacks Consensus Estimate of a loss of $0.37, and improved from a loss of $0.73 per share a year ago, representing an earnings surprise of 29.73% [1] - The company posted revenues of $12.01 million for the quarter ended June 2024, surpassing the Zacks Consensus Estimate by 74.51%, compared to revenues of $2.66 million in the same quarter last year [2] - Over the last four quarters, C4 Therapeutics has exceeded consensus EPS estimates two times and topped consensus revenue estimates two times [2] Stock Performance - C4 Therapeutics shares have increased approximately 18.6% since the beginning of the year, outperforming the S&P 500's gain of 15.8% [3] - The current Zacks Rank for C4 Therapeutics is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.37 on revenues of $9.4 million, and for the current fiscal year, it is -$1.56 on revenues of $26.48 million [7] - The outlook for the Medical - Biomedical and Genetics industry, where C4 Therapeutics operates, is currently in the top 35% of over 250 Zacks industries, suggesting a favorable environment for stock performance [8]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ________________________________________________ FORM 10-Q ________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Se ...

Preliminary Monotherapy Data from the Ongoing CFT1946 Phase 1 Trial in BRAF V600X Solid Tumors to be Presented at ESMO Congress 2024; Initiated Monotherapy Expansion Cohort in Melanoma and Combination Cohort with Cetuximab in Colorectal Cancer Cemsidomide Phase 1 Trial in Multiple Myeloma and non-Hodgkin's Lymphoma Continues to Progress through Dose Escalation; Data on Track for Q4 2024 Cash, Cash Equivalents and Marketable Securities of $295.7 million as of June 30, 2024; Expected to Provide Runway into 20 ...

Core Insights - C4 Therapeutics, Inc. is expected to report a quarterly loss of $0.37 per share, reflecting a year-over-year change of +49.3%, with revenues projected at $6.88 million, an increase of 158.7% from the previous year [1] Group 1: Stock Performance - C4 Therapeutics shares increased by 13.7% in the last trading session, closing at $7.38, with notable trading volume compared to typical sessions, and a total gain of 56.8% over the past four weeks [2] - The rise in stock price is linked to positive investor sentiment regarding the progress of C4's clinical pipeline, particularly the evaluation of cemsidomide (CFT7455) for multiple myeloma and non-Hodgkin lymphomas [3] Group 2: Earnings and Estimates - The consensus EPS estimate for C4 Therapeutics has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [5] - C4 Therapeutics holds a Zacks Rank of 3 (Hold), similar to Praxis Precision Medicines, which also has a consensus EPS estimate unchanged at -$2.39, representing a year-over-year change of +67.5% [5][6]

WATERTOWN, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that preliminary data from the monotherapy dose escalation portion of the ongoing Phase 1/2 clinical trial of CFT1946, a novel BiDAC™ degrader in mutant BRAF V600 solid tumors, will be presented as a mini oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024 taking ...

Company Overview - C4 Therapeutics, Inc. (C4T) is a clinical-stage biopharmaceutical company focused on advancing targeted protein degradation science to develop new medicines that can transform patients' lives [2][4] - The company is leveraging its TORPEDO® platform to design and optimize small-molecule medicines aimed at difficult-to-treat diseases, particularly in oncology [4] Clinical Trial Information - C4T announced preliminary data from the monotherapy dose escalation portion of the ongoing Phase 1/2 clinical trial of CFT1946, a novel BiDAC™ degrader targeting mutant BRAF V600 solid tumors [2][3] - The presentation of these preliminary results will take place at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain, on September 14, 2024 [2][3] - CFT1946 is designed to be potent and selective against BRAF V600X mutant targets and has shown activity in preclinical studies in models with BRAF V600E driven disease and those resistant to BRAF inhibitors [3] Drug Development Focus - CFT1946 is currently being studied in a Phase 1 dose escalation trial for BRAF V600X mutant solid tumors, including colorectal cancer, melanoma, and non-small cell lung cancer [3] - The company's degrader medicines aim to utilize the body's natural protein recycling system to degrade disease-causing proteins, potentially overcoming drug resistance and improving patient outcomes [4]